文献速递血栓与止血贫血与红细胞疾病造血干细胞移植与细胞治疗

罗米司亭治疗Wiskott-Aldrich综合征儿童血小板减少的疗效

Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome.
PubMed 文献 · Br J Haematol · 2020-10-31

血小板计数完全或部分原发缓解分别见于22例(33%)和18例(27%);即使无缓解组,治疗首月后出血事件风险也显著降至21%。

要点

  • 罗米司亭可使部分WAS患儿血小板计数获得完全或部分缓解。
  • 即使血小板无缓解,治疗首月后出血事件风险也显著降低至21%。
  • 罗米司亭可用于等待移植或放弃移植的WAS患儿以减少出血风险。

核心结论

  • 罗米司亭可用于提高WAS患儿血小板计数并降低危及生命的出血风险。

主要发现

  • 血小板计数完全原发缓解见于22例(33%),部分原发缓解见于18例(27%)。
  • 无缓解组治疗首月后出血事件风险显著降至21%。
  • 缓解趋势持久稳定,血小板计数无显著波动。

临床怎么用

  • 罗米司亭可用于等待造血干细胞移植或因各种原因放弃移植的WAS患儿。

局限性

  • 为回顾性分析,随访时间中位8个月(范围1-12个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Wiskott-Aldrich syndrome (WAS) is a life-threatening primary immunodeficiency associated with bleeding of variable severity due to thrombocytopenia. Correction of the thrombocytopenia is of paramount importance for most WAS patients. We report a retrospective analysis of the safety and efficacy of romiplostim treatment in reducing thrombocytopenia and bleeding tendency in 67 children (median age 1·3 years) with genetically confirmed WAS, followed in eight months (range, 1-12 months). Complete or partial primary responses regarding platelet counts were observed in 22 (33%) and 18 (27%) subjects, respectively. Yet, even in the non-responder group, the risk of haemorrhagic events decreased significantly, to 21%, after the first month of treatment. The responses tended to be durable and stable over time, with no significant fluctuations in platelets counts. The results of this retrospective study of a large cohort of WAS patients demonstrates that romiplostim can be used to increase platelet counts and reduce the risks of life-threatening bleeding in WAS patients awaiting haematopoietic stem cell transplantation or forgoing the procedure for various reasons.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Khoreva A, Abramova I, Deripapa E, et al. Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome. Br J Haematol. 2020. PMID: 33131064. doi:10.1111/bjh.17174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。